Skip to main content
SpringerLink
Log in

TIGER und die Hintergründe

Was tun beim Hodenkarzinomrezidiv nach Chemotherapie?

  • Fortbildung
  • Published:
Uro-News Aims and scope

Nach Erstdiagnose Hodenkarzinom werden nahezu alle Patienten in den frühen und der überwiegende Anteil der Patienten in den fortgeschrittenen Stadien geheilt. Im seltenen Fall des Rezidivs ist die optimale Therapie nicht eindeutig. Die Datenlage, aktuelle Empfehlungen und die zu dieser Frage laufende internationale TIGER-Studie sollen hier diskutiert werden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Fischer et al. Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma. J Clin Oncol. 2017; 35: 194–200

    Article  Google Scholar 

  2. International Prognostic Factors Study Group. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol. 2010; 28: 4906-11

  3. Adra et al. High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience. J Clin Oncol. 2016; 35: 1096–102

    Article  Google Scholar 

  4. Pico et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol. 2005; 16: 1152–9

    Article  Google Scholar 

  5. Lorch J et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. Clin Oncol. 2011; 29: 2178–84

    Article  Google Scholar 

  6. Feldmann DR et al. Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial. J Cancer. 2011; 2: 374–7

    Article  Google Scholar 

  7. Cathomas R et al. Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. J Clin Oncol. https://doi.org/10.1200/JCO.18.00210

    Article  CAS  Google Scholar 

  8. Feldmann DR. Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options—An Analysis From the Global Germ Cell Cancer Group. J Clin Oncol. 2016; 34: 345–51

    Article  Google Scholar 

  9. Sharp DS et al. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol. 2008; 26: 5524–9

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin, Vivantes Klinikum Am Urban, Dieffenbachstraße 1, 10967, Berlin, Deutschland

    Annette Dieing

Authors
  1. Annette Dieing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annette Dieing.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dieing, A. Was tun beim Hodenkarzinomrezidiv nach Chemotherapie?. Uro-News 23, 28–32 (2019). https://doi.org/10.1007/s00092-019-3017-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00092-019-3017-0

Search

Navigation